SCHEMBL25354038

SCHEMBL25354038

O=C1Nc2ccc(Br)cc2C(=O)N2CCN(Cc3ccncc3)CC12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IKZF2 Q9UKS7 2/20 0.43
▸ IKZF1 Q13422 1/20 0.43
▸ MEN1 O00255 2/20 0.38
▸ KMT2A Q03164 2/20 0.38
▸ STAT3 P40763 1/20 0.38
▸ NPSR1 Q6W5P4 1/20 0.38
▸ CXCR3 P49682 1/20 0.37
▸ DDB1 Q16531 1/20 0.35
▸ CRBN Q96SW2 1/20 0.35
▸ PARP1 P09874 2/20 0.35
▸ ALDH1A1 P00352 2/20 0.35
▸ KDM4E B2RXH2 1/20 0.35
▸ MAPT P10636 1/20 0.35
▸ TP53 P04637 1/20 0.35
▸ MDM2 Q00987 1/20 0.35
▸ HSD11B1 P28845 1/20 0.34
▸ GABRA1 P14867 1/20 0.34
▸ GABRA5 P31644 1/20 0.34
▸ GABRA3 P34903 1/20 0.34
▸ GABRA2 P47869 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30517888 0.88 MEN1 (0.37) IKZF2IKZF1MEN1KMT2ADDB1
SCHEMBL25353872 0.88 MEN1 (0.37) IKZF2IKZF1MEN1KMT2ADDB1
SCHEMBL25353734 0.85 NOTUM (0.47) CXCR3CRBN
SCHEMBL25353722 0.81 ALDH1A1 (0.55) MEN1KMT2AALDH1A1KDM4EMAPT
SCHEMBL25352010 0.81 PLK4 (0.41) MEN1KMT2AALDH1A1KDM4ETP53
SCHEMBL25353999 0.81 MEN1 (0.39) IKZF2MEN1KMT2AALDH1A1KDM4E
SCHEMBL25353201 0.81 CHRM3 (0.42) DDB1CRBNALDH1A1KDM4EMAPT
SCHEMBL30517878 0.81 CHRM3 (0.42) DDB1CRBNALDH1A1KDM4EMAPT
SCHEMBL25354047 0.78 ALDH1A1 (0.38) IKZF2MEN1KMT2ADDB1CRBN
SCHEMBL25999346 0.78 F9 (0.36) MEN1KMT2ADDB1CRBNALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250134907-A1 FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2025-05-01 — — US disclosed
EP-4476222-A1 FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF The United States of America, as represented by the Secretary, Department of Health and Human Services (US) 2024-12-18 — — EP disclosed
WO-2023154197-A1 FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-08-17 — — WO disclosed
WO-2023154197-A1 FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) 2023-08-17 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250134907-A1 FUSED DIAZEPINES AS AGONISTS OF THE INSULIN-LIKE 3 (INSL3) PEPTIDE RECEPTOR RXFP2 AND METHODS OF USE THEREOF RXFP3, RXFP4, RXFP2 IKZF2 619/4885IKZF1 772/4885MEN1 38/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback